Search Result

Results for "

Amyloid-β Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (29) Apoptosis (5) Autophagy (4) Beta-secretase (5) Calcium Channel (1) Casein Kinase (1) CDK (1) Cholinesterase (ChE) (7) Endogenous Metabolite (1) GSK-3 (1) HDAC (1) HIV (3) Isotope-Labeled Compounds (1) mAChR (1) Monoamine Oxidase (1) nAChR (2) NF-κB (2) NOD-like Receptor (NLR) (4) Notch (1) Nucleoside Antimetabolite/Analog (3) Organoid (1) PAI-1 (1) Reactive Oxygen Species (1) Reverse Transcriptase (3) Tau Protein (1) γ-secretase (1)
By Research Areas:	Cancer (4) Infection (3) Inflammation/Immunology (5) Neurological Disease (35)

By Targets:

Amyloid-β (29)

Apoptosis (5)

Autophagy (4)

Beta-secretase (5)

Calcium Channel (1)

Casein Kinase (1)

CDK (1)

Cholinesterase (ChE) (7)

Endogenous Metabolite (1)

GSK-3 (1)

HDAC (1)

HIV (3)

Isotope-Labeled Compounds (1)

mAChR (1)

Monoamine Oxidase (1)

nAChR (2)

NF-κB (2)

NOD-like Receptor (NLR) (4)

Notch (1)

Nucleoside Antimetabolite/Analog (3)

Organoid (1)

PAI-1 (1)

Reactive Oxygen Species (1)

Reverse Transcriptase (3)

Tau Protein (1)

γ-secretase (1)

By Research Areas:

Cancer (4)

Infection (3)

Inflammation/Immunology (5)

Neurological Disease (35)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50900

gamma-Secretase Modulators Amyloid-β production Inhibitor; γ-Secretase Modulators	Amyloid-β	Neurological Disease
gamma-Secretase Modulators (Amyloid-β production inhibitor) is a Amyloid-β production inhibitor.

HY-N0931

Santacruzamate A 5+ Cited Publications CAY-10683	HDAC Amyloid-β	Neurological Disease Cancer
Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC₅₀ of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research .

HY-17631A

Edonerpic maleate

T-817 maleate; T-817MA
Amyloid-β Neurological Disease

Edonerpic maleate is a novel neurotrophic agent which can inhibit amyloid-β peptides (Aβ).
HY-P3244

D-KLVFFA

Amyloid-β Neurological Disease

D-KLVFFA is the inhibitor of Amyloid-β assembly, with the IC₅₀ of 2.6 μM, that can be used in Alzheimer's disease study .
HY-153431

TRV-1387

Tau Protein Amyloid-β Neurological Disease

TRV-1387 is a benzofurazan that inhibits the aggregation of tau and amyloid-β .

Edonerpic maleate T-817 maleate; T-817MA	Amyloid-β	Neurological Disease
Edonerpic maleate is a novel neurotrophic agent which can inhibit amyloid-β peptides (Aβ).

D-KLVFFA	Amyloid-β	Neurological Disease
D-KLVFFA is the inhibitor of Amyloid-β assembly, with the IC₅₀ of 2.6 μM, that can be used in Alzheimer's disease study .

TRV-1387	Tau Protein Amyloid-β	Neurological Disease
TRV-1387 is a benzofurazan that inhibits the aggregation of tau and *amyloid-β* .

HY-139324

Cu(II)GTSM 1 Publications Verification	GSK-3 Amyloid-β	Neurological Disease
Cu(II)GTSM, a cell-permeable Cu-complex, significantly inhibits GSK3β. Cu(II)GTSM inhibits Amyloid-β oligomers (AβOs) and decreases tau phosphorylation. Cu(II)GTSM also decreases the abundance of Amyloid-β trimers. Cu(II)GTSM is a potential anticancer and antimicrobial agent .

HY-P1962

β-Secretase inhibitor [Asn670, Sta671, Val672]-Amyloid β Peptide (662-675)	Beta-secretase	Neurological Disease
β-Secretase inhibitor ([Asn670, Sta671, Val672]-Amyloid β Peptide (662-675)) is a β-secretase and BACE1 inhibitor (IC₅₀: 25 nM for β-secretase) .

HY-163441

BChE-IN-31	Cholinesterase (ChE)	Neurological Disease
BChE-IN-31 (Compound 14d) is a selective BChE inhibitor with an IC₅₀ of 65 nM. BChE-IN-31 inhibits the self-induced aggregation of neurotoxic amyloid-β (Aβ) peptide .

HY-N2319

Dihydroergocristine mesylate DHEC mesylate
Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease *amyloid-β* peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (K_d) of 25.7 nM and 9.8 μM, respectively .

HY-163320

AChE/Aβ-IN-5	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/Aβ-IN-5 (compound AV-2) is a bifunctional inhibitor that targets AChE and auto-induced Aβ (Amyloid-β) aggregation. AChE/Aβ-IN-5 can significantly improve scopolamine- and Aβ-induced cognitive impairment in mice .

HY-14759

Aleplasinin PAZ-417	PAI-1 Amyloid-β	Neurological Disease
Aleplasinin is an orally active, potent, BBB-penetrated and selectiveSERPINE1 (PAI-1, Plasminogen activator inhibitor-1) inhibitor. Aleplasinin increases amyloid-β (Aβ) catabolism and ameliorates amyloid-related pathology. Aleplasinin improves memory deficiency. Aleplasinin can be used for Alzheimer's disease research .

HY-W010041

Scyllo-Inositol	Amyloid-β Endogenous Metabolite	Neurological Disease
Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of *amyloid-β* peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model .

HY-P5124

β-Amyloid peptide(16-20) KLVFF	Amyloid-β	Neurological Disease
β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of *Amyloid-β* (Abeta). β-Amyloid peptide(16-20) is an effective inhibitor of Abeta fibril formation, with RG-/-GR-NH₂ residues added at N- and C-terminal ends to aid solubility) .

HY-N2319R

Dihydroergocristine mesylate (Standard) DHEC mesylate (Standard)	Amyloid-β	Neurological Disease
Dihydroergocristine (mesylate) (Standard) is the analytical standard of Dihydroergocristine (mesylate). This product is intended for research and analytical applications. Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease *amyloid-β* peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (K_d) of 25.7 nM and 9.8 μM, respectively .

HY-B0116

Stavudine 3 Publications Verification d4T	Reverse Transcriptase HIV Nucleoside Antimetabolite/Analog NOD-like Receptor (NLR) Autophagy Apoptosis	Infection
Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis .

HY-B0116A

Stavudine sodium d4T sodium	Reverse Transcriptase HIV Nucleoside Antimetabolite/Analog NOD-like Receptor (NLR) Autophagy Apoptosis	Infection
Stavudine (d4T) sodium is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine sodium has activity against HIV-1 and HIV-2. Stavudine sodium also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine sodium reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine sodium induces apoptosis .

HY-130244

BACE1-IN-5	Beta-secretase	Neurological Disease
BACE1-IN-5 (Compound 15) is a *β-site amyloid* precursor protein cleaving enzyme 1 (BACE1)** inhibitor with an IC₅₀ of 9.1 nM, and also inhibits cellular amyloid-β (Aβ) with an IC₅₀ of 0.82 nM. BACE1-IN-5 has a medicinal chemistry that improves hERG inhibition and P-gp efflux .

HY-126047B

(R)-(+)-Anatabine	NF-κB Amyloid-β nAChR	Neurological Disease Inflammation/Immunology
(R)-(+)-Anatabine is an less active R-enantiomer of Anatabine. Anatabine is a potent α4β2 nAChR agonist . Anatabine inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment .

HY-13027

DAPT Maximum Cited Publications 89 Publications Verification GSI-IX	Organoid γ-secretase Amyloid-β Autophagy Notch Apoptosis	Neurological Disease Inflammation/Immunology Cancer
DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC₅₀s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ₄₂, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment .

HY-B0116S

Stavudine-d4	Isotope-Labeled Compounds Reverse Transcriptase HIV Nucleoside Antimetabolite/Analog NOD-like Receptor (NLR) Autophagy Apoptosis	Infection
Stavudine-d₄ is the deuterium labeled Stavudine. Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis[1][2][3][4].

HY-19918A

Anatabine dicitrate	NF-κB Amyloid-β nAChR	Neurological Disease Inflammation/Immunology
Anatabine dicitrate is a tobacco alkaloid that can cross the blood-brain barrier. Anatabine dicitrate is a potent α4β2 nAChR agonist. Anatabine dicitrate inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine dicitrate has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment .

HY-157440

AChE/Aβ-IN-3	Amyloid-β Reactive Oxygen Species Cholinesterase (ChE)	Neurological Disease
AChE/Aβ-IN-3 (compound AM5) is a dual inhibitor of AChE and *Amyloid-β* aggregation with IC_50<.sub> values of 1.29 and 4.93 μM, respectively. AChE/Aβ-IN-3 has antioxidant properties that scavenge ROS and restore their normal levels. AChE/Aβ-IN-3 can be used in the study of neurological diseases, such as Alzheimer's disease .

HY-16009B

Buntanetap L-Tartrate (+)-Phenserine L-Tartrate; ANVS401 L-Tartrate	Amyloid-β	Cancer
Buntanetap (L-Tartrate) is an orally administered small molecule inhibitor of several neurotoxic proteins. Buntanetap reduces amyloid precursor protein (APP) production by blocking its mRNA translation .

HY-149211

AChE/BChE-IN-12	Cholinesterase (ChE) Beta-secretase Amyloid-β	Neurological Disease
AChE/BChE-IN-12 (compound 10b), a 3,5-dimethoxy analogue, is a potent AChE, BChE, and β-secretase-1 (BACE-1) inhibitor, with IC₅₀ values of 2.57, 3.26, and 10.65 μM, respectively. AChE/BChE-IN-12 crosses the blood-brain barrier via passive diffusion and inhibits the self-aggregation of *amyloid-β* monomers. AChE/BChE-IN-12 can be used for Alzheimer’s disease (AD) research .

HY-147820

AY1511

Amyloid-β Neurological Disease

AY1511 is an amyloid β (Aβ) aggregation inhibitor with low cytotoxicity .

AY1511	Amyloid-β	Neurological Disease
AY1511 is an amyloid β (Aβ) aggregation inhibitor with low cytotoxicity .

HY-146483

Anti-Aβ agent 1A	Amyloid-β	Neurological Disease Inflammation/Immunology
Anti-Aβ agent 1A (compound M15) has potent activity against *amyloid-β. Anti-Aβ agent 1A possesses can significantly inhibit* LPS-induced levels of IL-1β, IL-6 and TNF-α, and reduces the apoptosis of SH-SY5Y induced by H₂O₂ through mitochondria pathway. Anti-Aβ agent 1A possesses antioxidant, anti-inflammatory, anti-Aβ toxicity and neuroprotective activities. Anti-Aβ agent 1A can be used for researching Alzheimer’s disease (AD) .

HY-124322

NB-360	Beta-secretase	Neurological Disease Inflammation/Immunology
NB-360 is a potent, brain penetrable, and orally bioavailable dual BACE1/BACE2 inhibitor (IC₅₀: mouse and human BACE1=5 nM; BACE2=6 nM). NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in amyloid precursor protein(APP) transgenic mice. NB-360 can completely block the progression of Aβ deposition in the brains of APP transgenic mice. NB-360 shows excellent selectivity over the related aspartyl proteases pepsin, cathepsin D and cathepsin E .

HY-157296

AChE-IN-47	Cholinesterase (ChE)	Neurological Disease
AChE-IN-47 (compound g17) is a AChE inhibitor with the IC₅₀ of 0.24 μM. AChE-IN-47 inhibits amyloid β peptides self-aggregation. AChE-IN-47 displays neuroprotective effects and effectively suppresses the intracellular accumulation of reactive oxygen species .

HY-N1280

Semilicoisoflavone B	Amyloid-β	Neurological Disease
Semilicoisoflavone B, an isoflavone, mainly derived from Glycyrrhiza uralensis Fisch.. Semilicoisoflavone B reduces *amyloid β* (Aβ) secretion by inhibiting β-secretase-1 (BACE1) expression and activity. Semilicoisoflavone B decreases BACE1 expression mainly through increasing PPARγ expression and inhibiting STAT3 phosphorylation .

HY-N0249

Saikosaponin C	Amyloid-β	Neurological Disease
Saikosaponin C is a bioactive component found in radix bupleuri, targets *amyloid beta* and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression .

HY-146347

MAO-B-IN-10	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated MAO-B (monoamine oxidase-B) inhibitor, with IC₅₀ of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research .

HY-103383

(R)-DRF053 dihydrochloride	CDK Casein Kinase	Neurological Disease Cancer
(R)-DRF053 dihydrochloride is a potent casein kinases 1 (CK1), CDK1/cyclin B and CDK5/p25 inhibitor with IC₅₀s of 14 nM, 220 nM and 80 nM, respectively. (R)-DRF053 dihydrochloride prevents the CK1-dependent production of amyloid-beta in a cell model .

HY-146140

Aβ-IN-4	Amyloid-β	Neurological Disease
Aβ-IN-4 (compound 12) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-4 inhibits Aβ42 aggregation. However, Aβ-IN-4 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-4 can not change the aggregation state of Aβ42 into a nontoxic one .

HY-146139

Aβ-IN-3	Amyloid-β	Neurological Disease
Aβ-IN-3 (compound 1) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-3 inhibits Aβ42 aggregation. However, Aβ-IN-3 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-3 can not change the aggregation state of Aβ42 into a nontoxic one .

HY-120597

SAK3	Calcium Channel	Neurological Disease
SAK3 is a potent T-type voltage-gated Ca ²⁺ channels (T-VGCCs) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca ²⁺ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice . SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity .

HY-136813

Multitarget AD inhibitor-1	Beta-secretase Amyloid-β Cholinesterase (ChE)	Neurological Disease
Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC₅₀s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC_50hBACE-1=41.60 μM), *amyloid β* aggregation (IC_50Aβ=3.09 μM), tau aggregation. Multitarget AD inhibitor-1, a diphenylpropylamine derivative, has the potential for multifunctional disease-modifying anti-Alzheimer’s research .

HY-N0373

Licochalcone B 4 Publications Verification	Amyloid-β Apoptosis NOD-like Receptor (NLR)	Neurological Disease
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits *amyloid β* (₄₂) self-aggregation (IC₅₀=2.16 μM) and disaggregate pre-formed Aβ₄₂ fibrils, reduce metal-induced Aβ₄₂ aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-N6640

2-O-Acetyl-20-hydroxyecdysone 20-Hydroxyeedysone 2-acetate	Amyloid-β	Neurological Disease
2-O-Acetyl-20-hydroxyecdysone, an ecdysterones in insects and terrestrial plants, inhibits amyloid-β₄₂ (Aβ₄₂)-induced cytotoxicity. 2-O-Acetyl-20-hydroxyecdysone could decrease Aβ oligomer formation through promotion of fibrogenesis, transforming Aβ oligomers to the low-toxicity fibrils .

HY-149430

YIAD-0205	Amyloid-β	Neurological Disease
YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD transgenic mouse model with five familial AD mutations (5XFAD) .

HY-N8376

Fustin (±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone	Amyloid-β mAChR Cholinesterase (ChE)	Neurological Disease
Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) is a potent amyloid β (Aβ) inhibitor. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases the expression of acetylcholine (ACh) levels, choline acetyltransferase (ChAT) activity, and ChAT gene induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) decreases in acetyl cholinesterase (AChE) activity and AChE gene expression induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases muscarinic M1 receptor gene expression and muscarinic M1 receptor binding activity. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) can be used for Alzheimer's disease research .

β-Amyloid peptide(16-20) KLVFF	Amyloid-β	Neurological Disease
β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of *Amyloid-β* (Abeta). β-Amyloid peptide(16-20) is an effective inhibitor of Abeta fibril formation, with RG-/-GR-NH₂ residues added at N- and C-terminal ends to aid solubility) .

D-KLVFFA	Amyloid-β	Neurological Disease
D-KLVFFA is the inhibitor of Amyloid-β assembly, with the IC₅₀ of 2.6 μM, that can be used in Alzheimer's disease study .

β-Secretase inhibitor [Asn670, Sta671, Val672]-Amyloid β Peptide (662-675)	Beta-secretase	Neurological Disease
β-Secretase inhibitor ([Asn670, Sta671, Val672]-Amyloid β Peptide (662-675)) is a β-secretase and BACE1 inhibitor (IC₅₀: 25 nM for β-secretase) .

Amyloid-beta Antibody (MOAB-2)	Inhibitory Antibodies	Others
Amyloid-beta Antibody (MOAB-2) is a mouse-derived IgG2b, λ type antibody inhibitor, targeting to Amyloid-beta.

Cat. No.	Product Name	Category	Target	Chemical Structure